Lactobacillus reuteri 5454 and Bifidobacterium animalis ssp. lactis 5764 improve colitis while differentially impacting dendritic cells maturation and antimicrobial responses

[1]  C. Grangette,et al.  Probiotics in IBD: Combining in vitro and in vivo models for selecting strains with both anti-inflammatory potential as well as a capacity to restore the gut epithelial barrier , 2018, Journal of Functional Foods.

[2]  C. Grangette,et al.  New probiotic strains for inflammatory bowel disease management identified by combining in vitro and in vivo approaches. , 2018, Beneficial microbes.

[3]  C. Gamberi,et al.  Human Gut Microbiota: Toward an Ecology of Disease , 2017, Front. Microbiol..

[4]  C. Weaver,et al.  Citrobacter rodentium: a model enteropathogen for understanding the interplay of innate and adaptive components of type 3 immunity , 2017, Mucosal Immunology.

[5]  G. Wang,et al.  Lactobacillus reuteri I5007 Modulates Intestinal Host Defense Peptide Expression in the Model of IPEC-J2 Cells and Neonatal Piglets , 2017, Nutrients.

[6]  T. Kurita-Ochiai,et al.  Oral administration of Lactobacillus gasseri SBT2055 is effective in preventing Porphyromonas gingivalis-accelerated periodontal disease , 2017, Scientific Reports.

[7]  I. Chatterjee,et al.  Lactobacillus acidophilus counteracts inhibition of NHE3 and DRA expression and alleviates diarrheal phenotype in mice infected with Citrobacter rodentium. , 2016, American journal of physiology. Gastrointestinal and liver physiology.

[8]  A. Day,et al.  An overview of the bacterial contribution to Crohn disease pathogenesis. , 2016, Journal of medical microbiology.

[9]  Antonio Gasbarrini,et al.  Antibiotics as deep modulators of gut microbiota: between good and evil , 2016, Gut.

[10]  S. S. Cao.  Epithelial ER Stress in Crohn's Disease and Ulcerative Colitis , 2016, Inflammatory bowel diseases.

[11]  Á. Gil,et al.  The Role of Probiotic Lactic Acid Bacteria and Bifidobacteria in the Prevention and Treatment of Inflammatory Bowel Disease and Other Related Diseases: A Systematic Review of Randomized Human Clinical Trials , 2015, BioMed research international.

[12]  P. Vandenabeele,et al.  Necroptosis and its role in inflammation , 2015, Nature.

[13]  David M Richards,et al.  Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease , 2014, Clinical and experimental gastroenterology.

[14]  Erica C. Seth,et al.  Nutrient cross-feeding in the microbial world , 2014, Front. Microbiol..

[15]  G. Rogler,et al.  Probiotic Escherichia coli Nissle 1917 and Commensal E. coli K12 Differentially Affect the Inflammasome in Intestinal Epithelial Cells , 2014, Digestion.

[16]  A. De Luca,et al.  Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. , 2013, Immunity.

[17]  A. Young,et al.  Fecal Lipocalin 2, a Sensitive and Broadly Dynamic Non-Invasive Biomarker for Intestinal Inflammation , 2012, PloS one.

[18]  C. Grangette,et al.  Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide , 2011, Gut.

[19]  Tariq Ahmad,et al.  Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci , 2010, Nature Genetics.

[20]  J. Zizka,et al.  Cytokine expression in cord blood cells of children of healthy and allergic mothers , 2010, Folia Microbiologica.

[21]  Fiona Powrie,et al.  An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer , 2010, The Journal of experimental medicine.

[22]  Xiaojing Ma,et al.  Role of Nod2 in the development of Crohn's disease. , 2009, Microbes and infection.

[23]  K. Fellermann,et al.  Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn’s disease , 2009, Alimentary pharmacology & therapeutics.

[24]  Richard A Flavell,et al.  A protective function for interleukin 17A in T cell–mediated intestinal inflammation , 2009, Nature Immunology.

[25]  I. Petersen,et al.  Prevalence of infectious pathogens in Crohn's disease. , 2009, Pathology, research and practice.

[26]  Erin E. Murphy,et al.  Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation , 2009, The Journal of experimental medicine.

[27]  K. Zimmermann,et al.  Probiotic E. coli treatment mediates antimicrobial human β-defensin synthesis and fecal excretion in humans , 2009, Mucosal Immunology.

[28]  K. Karimi,et al.  Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice. , 2009, American journal of respiratory and critical care medicine.

[29]  R. Broaddus,et al.  Regulation of inflammatory responses by IL-17F , 2008, The Journal of experimental medicine.

[30]  K. Fellermann,et al.  Probiotic lactobacilli and VSL#3 induce enterocyte β‐defensin 2 , 2008, Clinical and experimental immunology.

[31]  S. Liddell,et al.  Impaired luminal processing of human defensin-5 in Crohn's disease: persistence in a complex with chymotrypsinogen and trypsin. , 2008, The American journal of pathology.

[32]  L. Simms,et al.  Reduced α-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn’s disease , 2008, Gut.

[33]  B. Becher,et al.  IL-22 Is Expressed by Th17 Cells in an IL-23-Dependent Fashion, but Not Required for the Development of Autoimmune Encephalomyelitis1 , 2007, The Journal of Immunology.

[34]  J. Sirard,et al.  A Key Role of Dendritic Cells in Probiotic Functionality , 2007, PloS one.

[35]  D. Relman,et al.  The role of microbes in Crohn's disease. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  D. Brassart,et al.  Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. , 2007, World journal of gastroenterology.

[37]  B. Foligné,et al.  Recommendations for Improved Use of the Murine TNBS-Induced Colitis Model in Evaluating Anti-inflammatory Properties of Lactic Acid Bacteria: Technical and Microbiological Aspects , 2006, Digestive Diseases and Sciences.

[38]  M. Weichenthal,et al.  Reduced Paneth cell α-defensins in ileal Crohn's disease , 2005 .

[39]  P. Sherman,et al.  Amelioration of the effects of Citrobacter rodentium infection in mice by pretreatment with probiotics. , 2005, The Journal of infectious diseases.

[40]  Richard A. Flavell,et al.  Nod2-Dependent Regulation of Innate and Adaptive Immunity in the Intestinal Tract , 2005, Science.

[41]  J. Hugot,et al.  Gene–environment interaction modulated by allelic heterogeneity in inflammatory diseases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Shellito,et al.  Requirement of Interleukin 17 Receptor Signaling for Lung Cxc Chemokine and Granulocyte Colony-Stimulating Factor Expression, Neutrophil Recruitment, and Host Defense , 2001, The Journal of experimental medicine.

[43]  C. Fuqua,et al.  Bacterial competition: surviving and thriving in the microbial jungle , 2010, Nature Reviews Microbiology.

[44]  M. Weichenthal,et al.  Reduced Paneth cell alpha-defensins in ileal Crohn's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. Andoh,et al.  Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. , 2004, Clinical immunology.

[46]  J. Wallace,et al.  Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. , 1989, Gastroenterology.